Glibenclamide-metformin combination for the treatment of diabetes mellitus of type II
AssigneeAbiogen Pharma S.P.A.
InventorsGiulio Barelli, Massimo De Regis
Life of this patent
Estimating the term…
Abstract
Non-insulin dependent diabetes mellitus in cases of secondary failure is treated with a combination of glibenclamide and metformin.
Claims7
A method of treating non-insulin dependent diabetes mellitus in cases of secondary failure comprising administering to a subject a need of same to a treatment utilizing a combination of glibenclamide and metformin, expressed as the glibenclamide-metformin hydrochloride in a weight ratio higher than 1:100, comprising administering to a subject in need of same a combination of glibenclamide and metformin, expressed as the hydrochloride, in a weight ratio higher than of 1:100.
A method of treating non-insulin dependent diabetes mellitus in cases of secondary failure comprising administering to a subject in need of same to a treatment utilizing a combination of glibenclamide-metformin hydrochloride in a weight ratio of 1:160 to 1:200, comprising administering to a subject in need of same a combination of glibenclamide and metformin, expressed as the hydrochloride, in a weight ratio of 1:160 to 1:200 1:100.
Dependencies are inferred from the claim text.